Deleterious brain cell membrane effects after NMDA receptor antagonist administration to newborn piglets

Brain Research

Volumn 816, Issue 2, 1999, Pages 438-445

  Fritz, Karen I ^a   Groenendaal, Floris ^b   Andersen, Carol ^a   Ohnishi, S Tsuyoshi ^c   Mishra, Om P ^a   Delivoria Papadopoulos, Maria ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Philadelphia Biomedical Research Institute   (United States)

Author keywords

Brain; CPP; Free radical; Lipid peroxidation; Newborn; NMDA receptor

Indexed keywords

4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ALKADIENE; CREATINE PHOSPHATE; GLUCOSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXYGEN RADICAL;

ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL METABOLISM; CONTROLLED STUDY; ENERGY METABOLISM; GLUCOSE UTILIZATION; LIPID PEROXIDATION; MEMBRANE STRUCTURE; NERVE CELL MEMBRANE; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ANIMALS, NEWBORN; CELL MEMBRANE; CEREBRAL CORTEX; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICALS; GLUCOSE; LIPID PEROXIDATION; PIPERAZINES; REACTIVE OXYGEN SPECIES; SWINE;

EID: 0033596587     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01178-0     Document Type: Article

References (41)

1. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31.
2. Bullock R., Graham D.I., Min-Hsiung C., Lowe D., McCulloch J. Focal cerebral ischemia in the cat: pretreatment with a competitive NMDA receptor antagonist, D-CPP-ene. J. Cereb. Blood Flow. 10:1990;668-674.
3. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Ann. Rev. Neurosci. 13:1990;171-182.
4. Constantine-Paton M., Cline H.T., Debski E. Patterned activity, synaptic convergence, and the NMDA receptor in developing visual pathways. Ann. Rev. Neurosci. 13:1990;129-154.
5. Dillard C.J., Tappel A.L. Fluorescent damage products of lipid peroxidation. Methods Enzymol. 105:1984;331-337.
6. Dirnagl U., Tanabe J., Pulsinelli W. Pre and post-treatment with MK-801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. Brain Res. 527:1990;62-68.
7. G-nitro-L-arginine and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. Eur. J. Pharm. 299:1996;9-16.
8. Folch J., Lees M.J., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissue. J. Biol. Chem. 226:1957;497-509.
9. Fragoso-Veloz J., Tapia R. NMDA receptor antagonists protect against seizures and wet-dog shakes induced by 4-aminopyridine. Eur. J. Pharm. 221:1992;275-280.
10. Fritz K.I., Groenendaal F., McGowan J.E., Mishra O.P., Delivoria-Papadopoulos M. Effect of cerebral Hypoxia on NMDA receptor binding characteristics after treatment with 3-(carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) in newborn piglets. Brain Res. 729:1996;66-74.
11. Gilland E., Hagberg H. NMDA receptor-dependent increase of cerebral glucose utilization after hypoxia-ischemia in the immature rat. J. Cereb. Blood Flow Metab. 16:1996;1005-1013.
12. +-ATPase modification following hypoxia in the guinea pig fetus. Neurosci. Lett. 153:1993;93-97.
13. Hargreaves R.J., Rigby M., Smith D., Hill R.G., Iverson L.L. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 18:1993;1263-1269.
14. Hargreaves R.J., Hill R.G., Iversen L.L. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochirurgica-Supplementum. 60:1994;15-19.
15. Harik S.I., Douli G.H., Dick A.P.K. Specific ouabain binding to brain microvessels and choroid plexus. J. Cereb. Blood Flow Metab. 5:1985;6-160.
16. Herrling P.L. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist: results from animal models and first results in humans. Neuropsychopharmacology. 10:1994;591S.
17. Ikonomidou C., Qin Y., Labruyere J., Kirby C., Olney J. Prevention of trauma-induced neurodegeneration in infant rat brain. Ped. Res. 39:1996;1020-1026.
18. Inglis F., Kuroda Y., Bullock R. Glucose hypermetabolism after acute subdural hematoma is ameliorated by competitive NMDA antagonist. J. Neurotrauma. 9(2):1992;75-84.
19. Jing J., Aitken P.G., Somjen G.G. Role of calcium channels in spearing depression in rat hippocampal slices. Brain Res. 604:1993;251-259.
20. Kristensen J.D., Post C., Gordh T., Svensson B.A. Spinal cord morphology and antinociception after chronic intrathecal administration of excitatory amino acid antagonists in the rat. Pain. 54:1993;309-316.
21. Kurumaji A., Nehls D.G., Park C.K., McCulloch J. Effects of NMDA antagonists, MK-801 and CPP upon local cerebral glucose use. Brain Res. 496:1989;268-284.
22. V. Lamprecht, H.U. Bergmeyer (Eds.), Creatine Phosphate: Methods of Enzymatic Analysis. Academic Press, 1974, pp. 1777-1781.
23. Laptook A.R., Corbett R.J.T., Arencibia-Mireles O., Ruley J. Glucose-associated alterations in ischemic brain metabolism of neonatal piglets. Stroke. 23:1992;1504-1511.
24. Lehmann J. CPP, a selective N-Methyl-D-Aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 240:1987;737-746.
25. Lesch K.P., Aulakh C.S., Wolozin B.L., L Hill J., Murphy D.L. 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid decreases NMDA receptor mRNA. Eur. J. Pharmacol. 227:1992;109-111.
26. Linden D.J. Long-term synaptic depression in the mammalian brain. Neuron. 12:1994;457-472.
27. Loubinoux I., Meric P., Borredon J., Correze J.L., Gillet B., Beloeil J.C., Tiffon B., Mispelter J., Lhoste J.M., Jacques S. Cerebral metabolic changes induced by MK-801: a 1D (phosphorus and proton) and 2D (proton) in vivo NMR spectroscopy study. Brain Res. 643:1994;115-124.
28. Lowry O.et al. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Marvizon J.C., Baudry M. NMDA receptor activation by spermine requires glutamate but not glycine. Eur. J. Pharmacol. (Mol. Pharm. section). 244:1993;103-104.
30. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15:1990;41-70.
31. +, and strophanthidin in vitro. Neurochem. Res. 14:1989;845-851.
32. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
33. Recknagel R.O., Glende E.A. Spectrophotometric detection of lipid conjugated dienes. Methods Enzymol. 105:1984;331-337.
34. Ren J.M., Gulve E.A., Cartee G.D., Holloszy J.O. Hypoxia causes glycogenolysis without an increase in percent phosphorylase in a rat skeletal muscle. Am. J. Physiol. 263:1992;E1086-1091.
35. Sakamoto A., Ohnishi S.T., Ohnishi T., Ogawa R. Relationship between free radical production and lipid peroxidation during ischemia-reperfusion injury in the rat brain. Brain Res. 554:1991;186-192.
36. Sakamoto A., Ohnishi S.T., Ohnishi T., Ogawa R. Protective effect of a new anti-oxidant on the rat brain exposed to ischemia-reperfusion injury: inhibition of free radical formation and lipid peroxidation. Free Radical Biol. Med. 11:1991;385-389.
37. Sharkey J., Ritchie I.M., Butcher S.P., Kelly J.S. Comparison of the patterns of altered cerebral glucose utilization produced by competitive and non-competitive NMDA receptor antagonists. Brain Res. 735:1996;67-82.
38. Torres G., Rivier C. Cocaine-induced expression of striatal C-fos in the rat is inhibited by NMDA receptor antagonists. Brain Res. Bullet. 30:1993;173-176.
39. Vannucci R.C. Experimental biology of cerebral hypoxia-ischemia: Relation to perinatal brain damage. Ped. Res. 27:1990;317-326.
40. Watson B.D. Evaluation of the concomitance of lipid peroxidation in experimental models of cerebral ischemia and stroke. Progress Brain Res. 96:1993;69-95.
41. Yeagle P.L. Lipid regulation of cell membrane structure and function. FASEB J. 3:1989;1833-1842.